Clinical management of patients at inherited risk for gynecologic cancer

Current Opinion in Obstetrics and Gynecology

Volumn 27, Issue 1, 2015, Pages 14-22

  Powell, C Bethan ^a  

^a KAISER PERMANENTE MEDICAL CENTER   (United States)

Author keywords

BRCA mutations; ovarian cancer; risk reduction

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; ORAL CONTRACEPTIVE AGENT;

BREAST CANCER; CANCER MORTALITY; CANCER PATIENT; CANCER RISK; CHEMOPROPHYLAXIS; COWDEN SYNDROME; FOLLOW UP; GENE MUTATION; GYNECOLOGIC CANCER; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; HYSTERECTOMY; INHERITANCE; LIFESTYLE; ORAL CONTRACEPTIVE USE; OVARY CANCER; PERITONEUM CANCER; PEUTZ JEGHERS SYNDROME; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SALPINGECTOMY; SALPINGOOOPHORECTOMY; SURGICAL TECHNIQUE; UTERINE TUBE; DISEASE FREE SURVIVAL; FEMALE; GENETIC COUNSELING; GENETIC PREDISPOSITION; GENETICS; GENITAL NEOPLASMS, FEMALE; MUTATION; OVARIECTOMY; PRACTICE GUIDELINE; PROCEDURES; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SENTINEL SURVEILLANCE; THEORETICAL MODEL; TUMOR SUPPRESSOR GENE;

CHEMOPREVENTION; CONTRACEPTIVES, ORAL, HORMONAL; DISEASE-FREE SURVIVAL; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC COUNSELING; GENETIC PREDISPOSITION TO DISEASE; GENITAL NEOPLASMS, FEMALE; HUMANS; MODELS, THEORETICAL; MUTATION; OVARIECTOMY; PRACTICE GUIDELINES AS TOPIC; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; RISK REDUCTION BEHAVIOR; SENTINEL SURVEILLANCE;

EID: 84920819288     PISSN: 1040872X     EISSN: 1473656X     Source Type: Journal    
DOI: 10.1097/GCO.0000000000000143     Document Type: Review

References (64)

1. http://www.nccn.org/professionals/physician-gls/pdf/genetics-screening.pdf 1.2014, HBOC management, 1-2. [Accessed 9 May 2014]
2. Chen S, Parmigiani G. Meta-Analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 2007; 25:1329-1333.
3. Walsh T, Casadeia S, Lee MK, et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci U S A 2011; 108:18032-18037.
4. Loveday C, Turnbull C, Ramsay E, et al. Germline mutations in RAD51D confer susceptibility to ovarian cancer. Nat Genet 2011; 43:879-882.
5. Loveday C, Turnbull C, Ruark E, et al. Germline RAD51C mutations confer susceptibility to ovarian cancer. Nat Genet 2012; 44:475-476.
6. Rafnar T, Gudbjartsson DF, Sulem P, et al. Mutations in BRIP1 confer high risk of ovarian cancer. Nat Genet 2011; 43:1104-1107.
7. Casadei S, Norquist BM, Walsh T, et al. Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer. Cancer Res 2011; 71:2222-2229.
8. Rio Frio T, Bahubeshi A, Kanellopoulou C, et al. DICER1 mutations in familial multinodular goiter with and without ovarian Sertoli-Leydig cell tumors. JAMA 2011; 305:68-77.
9. Sabbaghian N, Srivastava A, Hamel N, et al. Germ-line deletion in DICER1 revealed by a novel MLPA assay using synthetic oligonucleotides. Eur J Hum Genet 2014; 22:564-567.
10. Kupryjanczyk J, Dansonka-Mieszkowska A, Moes-Sosnowska J, et al. Ovarian small cell carcinoma of hypercalcemic type - evidence of germline origin and SMARCA4 gene inactivation: a pilot study. Pol J Pathol 2013; 64:238-246.
11. Witkowski L, Carrot-Zhang J, Albrecht S, et al. Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type. Nat Genet 2014; 46:438-443.
12. Ramos P, Karnezis AN, Craig DW, et al. Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4. Nat Genet 2014; 46:427-429.
13. Jelinic P, Mueller JJ, Olvera N, et al. Recurrent SMARC4 mutations in small cell carcinoma of the ovary. Nat Genet 2014; 46:424-426.
14. http://www.nccn.org/professionals/physician-gls/pdf/genetics-colon.pdf, 2.2014, LS-D. [Accessed 9 April 2014]
15. Barrow E, Hill J, Evans DG. Cancer risk in Lynch syndrome. Fam Cancer 2013; 12:229-240.
16. Senter L, Clendenning M, Sotamaa K, et al. The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. Gastroenterology 2008; 135:419-428.
17. Pilarski R. Cowden syndrome: a critical review of the clinical literature. J Genet Couns 2009; 18:13-27.
18. Riegert-Johnson D, Gleeson B. Friebel T, Domchek SM, Rebbeck TR. Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: a systematic review and meta-Analysis. JNCI 2014; 106:1-14.
19. McGee J, Kotsopoulos J, Lubinski J, et al. Anthropometric measures and risk of ovarian cancer among BRCA1 and BRCA2 mutation carriers. Obesity 2012; 20:1288-1292.
20. Finch A, Valentini A, Greenblatt E, et al. Frequency of premature menopause in women who carry a BRCA1 or BRCA2 mutation. Fertil Steril 2013; 99:1724-1728.
21. Derks-Smeets IA, Gietel-Habets J, Tibben A, et al. Decision-making on preimplantation genetic diagnosis and prenatal diagnosis: a challenge for couples with hereditary breast and ovarian cancer. Hum Reprod 2014; 29:1103-1112.
22. Moorman PG, Havrilesky LJ, Gierisch JM, et al. Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-Analysis. J Clin Oncol 2013; 31:4188-4198.
23. Kotsopoulos J, Lubinski J, Moller P, et al. Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers. Breast Cancer Res Treat 2014; 143:579-586.
24. Long KC, Kauff ND. Screening for familial ovarian cancer: a ray of hope and a light to steer by. J Clin Oncol 2013; 31:8-10.
25. Rosenthal AN, Fraser L, Manchanda R, et al. Results of annual screening in phase I of the United Kingdom familial ovarian cancer screening study highlight the need for strict adherence to screening schedule. J Clin Oncol 2013; 31:49-57.
26. Menon U, Griffin M, Gentry-Maharaj A. Ovarian cancer screening: current status, future directions. Gynecol Oncol 2014; 132:490-495.
27. Lu KH, Skates S, Hernandez MA, et al. A 2-stage ovarian cancer screening strategy using the risk of ovarian cancer algorithm (ROCA) identifies earlystage incident cancers and demonstrates high positive predictive value. Cancer 2013; 119:3454-3461.
28. Andersen MR, Lowe KA, Goff BA. Value of symptom-triggered diagnostic evaluation for ovarian cancer. Obstet Gynecol 2014; 123:73-79.
29. Otsuka I, Kameda S, Hoshi K. Early detection of ovarian and fallopian tube cancer by examination of cytological samples from the endometrial cavity. Br J Cancer 2013; 109:603-609.
30. Kinde I, Bettegowda C, Wang Y, et al. Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers. Sci Transl Med 2013; 5:1-21.
31. McAlpine JN, El Hallani S, Lam SF, et al. Autofluorescence imaging can identify preinvasive or clinically occult lesions in fallopian tube epithelium: a promising step towards screening and early detection. Gynecol Oncol 2011; 120:385-392.
32. Finch A, Lubinski J, Moller P, et al. The impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol 2014; 32:1547-1553.
33. Eisen A, Lubinski J, Klijn J, Moller P. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-controlled study. J Clin Oncol 2005; 23:7491-7496.
34. Kotsopoulos J, Lubinski J, Lynch HT, et al. Oophorectomy after menopause and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev 2012; 21:1089-1096.
35. American College of Obstetricians and Gynecologists, ACOG Committee on Practice Bulletins - Gynecology, ACOG Committee on Genetics, Society of Gynecologic Oncologists. ACOG practice bulletin no. 103: hereditary breast and ovarian cancer syndrome. Obstet Gynecol 2009; 113:957-966.
36. Powell CB. Risk reducing salpingo-oophorectomy for BRCA mutation carriers: twenty years later. Gynecol Oncol 2014; 132:261-263.
37. Powell CB, Swisher EM, Cass I, et al. Long term follow up of BRCA1 and BRCA2 mutation carriers with unsuspected neoplasia identified at risk reducing salpingo-oophorectomy. Gynecol Oncol 2013; 129:364-371.
38. Connor JR, Meserve E, Pizer E, et al.Outcome of unexpected adnexal neoplasia discovered during risk reducing salpingo-oophorectomy in women with germline BRCA1 or BRCA2 mutations. Gynecol Oncol 2014; 132:280-286.
39. Hanwright P, Mioto LM, Thomassee MS, et al. Risk profiles and outcomes of total laparoscopic hysterectomy compared with laparoscopically assisted vaginal hysterectomy. Obstet Gynecol 2013; 121:781-787.
40. Segev Y, Iqbal J, Lubinski J, et al. The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: an international prospective cohort study. Gynecol Oncol 2013; 130:127-131.
41. Reitsma W, Mourits MJ, d Bock GH, Hollema H. Endometrium is not the primary site of origin of pelvic high-grade serous carcinoma in BRCA1 or BRCA2 mutation carriers. Mod Pathol 2013; 26:572-578.
42. Shu CA, Pike M, Jotwani AR et al. Risk of developing uterine corpus cancer (Ut Ca) following risk-reducing salpingo-oophorectomy (RRSO) in women with BRCA mutations [abstract]. Abstract presented at Society of GynecologicOncologists, Tampa, FL, March 2014.
43. Pennington KP, Walsh T, Lee M, et al. BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinoma. Cancer 2013; 119:332-338.
44. Vyarvelska I, Rosen B, Narod S. Should hysterectomy complement prophylactic salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers? Gynecol Oncol 2014; 134:219-221.
45. Medeiros F, Muto MG, Lee Y, et al. The tubal epithelium is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol 2006; 30:230-236.
46. Salvador S, Rempel A, Soslow RA, et al. Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and frequent monoclonality of synchronous ovarian and fallopian tube mucosal serous carcinoma. Gynecol Oncol 2008; 110:408-417.
47. OShannessy DJ, Jackson SM, Twine NC, et al. Gene expression analyses support fallopian tube epithelium as the cell of origin of epithelial ovarian cancer. Int J Mol Sci 2013; 14:13687-13703.
48. Gao FF, Bhargava R, Yang H, et al. Clinicopathologic study of serous tubal intraepithelial carcinoma with invasive carcinoma: is serous tubal intraepithelial carcinoma a reliable feature for determining the organ of origin? Hum Pathol 2013; 44:1534-1543.
49. Antoniou AC, Rookus M, Andrieu N, et al. Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: results from the Internation BRCA1/2 Carrier Cohort Study. Cancer Epidemiol Biomarkers Prev 2009; 18:601-610.
50. Garcia C, Wendt J, Lyon L, et al. Risk management options elected by women after testing positive for a BRCA mutation. Gynecol Oncol 2014; 132:428-433.
51. Holman LL, Friedman S, Daniels MS, et al. Acceptability of prophylactic salpingectomy with delayed oophorectomy as risk-reducing surgery among BRCA mutation carriers. Gynecol Oncol 2014; 133:283-286.
52. Kwon JS, Tinker A, Pansegrau G, et al. Prophylactic salpingectomy and delayed oophorectomy as an alternative for BRCA mutation carriers. Obstet Gynecol 2013; 121:14-24.
53. Findley AD, Siedhoff MT, Hobbs KA, et al. Short-term effects of salpingectomy during laparoscopic hysterectomy on ovarian reserve: a pilot randomized controlled trial. Fertil Steril 2013; 100:1704-1708.
54. Vorwergk J, Radosa MP, Nicolaus K, et al. Prophylactic bilateral salpingectomy (PBS) to reduce ovarian cancer risk incorporated in standard premenopausal hysterectomy: complications and re-operation rate. J Cancer Res Clin Oncol 2014; 140:859-865.
55. Morelli M, Venturella R, Mocciaro R, et al. Prophylactic salpingectomy in premenopausal low-risk women for ovarian cancer: primum non nocere. Gynecol Oncol 2013; 129:448-451.
56. McAlpine J, Hanley G, Woo M, et al. Opportunistic salpingectomy: uptake, risks, and complications of a regional initiative for ovarian cancer prevention. Am J Obstet Gynecol 2014; 210:471.e1-471.e11.
57. Lu KH, Dinh M, Kohlmann W, et al. Gynecologic cancer as a sentinel cancer for women with hereditary nonpolyposis colorectal cancer syndrome. Obstet Gynecol 2005; 105:567-574.
58. Renkonen-Sinisalo L, Butzow R, Leminen A, et al. Surveillance for endometrial cancer in hereditary nonpolyposis colorectal cancer syndrome. Int J Cancer 2007; 120:821-824.
59. Palma L, Marcus V, Gilbert L, et al. Synchronous occult cancers of the endometrium and fallopian tube in an MSH2 mutation carrier at time of prophylactic surgery. Gynecol Oncol 2008; 111:575-578.
60. Lu KH, Loose DS, Yates MS, et al. Prospective multicenter randomized intermediate biomarker study of oral contraceptive versus depo-provera for prevention of endometrial cancer in women with lynch syndrome. Cancer Prev Res 2013; 6:774-781.
61. Aarnio M, Melkin JP, Aaltonen LA, et al. Life-time risk of different cancers in hereditary nonpolyposis colorectal cancer (HNPCC) syndrome. Int J Cancer 1995; 64:430-433.
62. Schmeler KM, Lynch HT, Chen LM, et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 2006; 354:261-269.
63. GeneReviews: Peutz Jegher syndrome http://www.ncbi.nlm.nih.gov/books/NBK1266/last. [Accessed 9June 2014].
64. Metcalfe KA, Kim-Sing C, Ghadirian P, et al. Healthcare provider recommendation for reducing cancer risks among women with BRCA1 or BRCA2 mutation. Clin Genet 2014; 85:21-30.